Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: RO4998452Drug: placebo
- First Posted Date
- 2008-05-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT00682097
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
Phase 3
Terminated
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT00680563
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT00679341
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 207
- Registration Number
- NCT00674973
A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes
Not Applicable
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Device: Accu-Chek 360° View Blood Glucose Analysis ToolDevice: Accu-Chek Aviva Glucose Meter
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 522
- Registration Number
- NCT00674986
Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Phase 2
Completed
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- Drug: TRO19622
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT00666016
- Locations
- 🇫🇷
Hôpital Archet 2 - Pôle de Référence Hépatite C (Niveau -2) - 151, route Saint Antoine de Ginestière, Nice, France
🇫🇷Groupe Hospitalier Pitié-Salpétrière - Sce Hépato-Gastroentérologie - 47-83 Bd de l'Hôpital, Paris, France
A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 132
- Registration Number
- NCT00661505
- Locations
- 🇹🇷
Adnan Menderes Uni School of Medicine; Physical Therapy & Rehabilitation, Aydin, Turkey
🇹🇷Trakya University Medical Faculty; Internal Medicine; Nephrology, Edirne, Turkey
🇹🇷Izmir Ataturk Research and Training Hospital; The Clinic of Nephrology, Izmir, Turkey
A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 75
- Registration Number
- NCT00661388
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 598
- Registration Number
- NCT00661102
ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B
Phase 3
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: adefovir dipivoxilDrug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT00661076
© Copyright 2025. All Rights Reserved by MedPath